CN111662235B - Benzoyl pyridazine derivative and preparation method thereof - Google Patents

Benzoyl pyridazine derivative and preparation method thereof Download PDF

Info

Publication number
CN111662235B
CN111662235B CN202010578951.2A CN202010578951A CN111662235B CN 111662235 B CN111662235 B CN 111662235B CN 202010578951 A CN202010578951 A CN 202010578951A CN 111662235 B CN111662235 B CN 111662235B
Authority
CN
China
Prior art keywords
formula
derivative
benzoyl
benzoylpyridazine
compound shown
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202010578951.2A
Other languages
Chinese (zh)
Other versions
CN111662235A (en
Inventor
王胜强
王妍芳
徐启杰
李洋
范雨轩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Huanghuai University
Original Assignee
Huanghuai University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Huanghuai University filed Critical Huanghuai University
Priority to CN202010578951.2A priority Critical patent/CN111662235B/en
Publication of CN111662235A publication Critical patent/CN111662235A/en
Application granted granted Critical
Publication of CN111662235B publication Critical patent/CN111662235B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/08—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/12—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C07D237/16—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The invention relates to a benzoyl pyridazine derivative and a preparation method thereof, belonging to the field ofThe technical field of pyridazine compound synthesis. The benzoylpyridazine derivative of the present invention has a structure represented by formula 1 or formula 2:r1 is any one of hydrogen, halogen, hydroxyl, alkyl, alkoxy, substituted alkoxy, aryl, heteroaryl, cyano, ester and benzoyl; r2 is any one of hydrogen, halogen, hydroxyl, alkyl, alkoxy, substituted alkoxy, aryl, heteroaryl, cyano, ester and benzoyl; and R3 is any one of aryl and aryl hetero-radical. The benzoyl pyridazine derivative has the advantages of short synthetic route, simple operation, stable raw materials and lower cost, and is suitable for large-scale production.

Description

Benzoyl pyridazine derivative and preparation method thereof
Technical Field
The invention relates to a benzoyl pyridazine derivative and a preparation method thereof, belonging to the technical field of pyridazine compound synthesis.
Background
The pyridazine derivatives are compounds with very wide application, and can be applied to a plurality of fields such as new medicine research and development, agricultural chemicals, high polymer materials and the like. The pyridazine derivative is generally obtained by introducing other substituent groups on a pyridazine ring, and the mode also enables the pyridazine compound to have more and wider development space. However, pyridazines are diazines, and the high electron-deficient nature makes acylation of the pyridazine ring very difficult. The conventional Friedel-Crafts acylation method is not suitable for the acylation of electron-deficient pyridazine rings.
The existing method for synthesizing the acyl pyridazine compounds mainly adopts a multi-step reaction or a method using a metal reagent (shown below), and the methods generally have the problems of long reaction route, low overall yield and the like, and the application range of a substrate is easy to be limited.
In the aryl (hetero) formyl pyridazine derivatives (such as benzoyl pyridazine derivatives), due to the existence of aryl (hetero) formyl radicals, the aryl (hetero) formyl pyridazine derivatives have good application prospect, and the development of a method for preparing the aryl (hetero) formyl pyridazine derivatives, which is simple in operation and short in route, has great significance.
Disclosure of Invention
The invention provides a benzoyl pyridazine derivative. The invention also provides a preparation method of the benzoyl pyridazine derivative, which is simple to operate and has higher yield.
The technical scheme adopted by the invention for solving the technical problems is as follows:
a benzoylpyridazine derivative having a structure represented by formula 1 or formula 2:
r1 is any one of hydrogen, halogen, hydroxyl, alkyl, alkoxy, substituted alkoxy, aryl, heteroaryl, cyano, ester and benzoyl;
r2 is any one of hydrogen, halogen, hydroxyl, alkyl, alkoxy, substituted alkoxy, aryl, heteroaryl, cyano, ester and benzoyl;
and R3 is any one of methyl, aryl and aryl hetero-radical.
For R1 and R2, preferably, the halogen is any one of Cl, br and I. The alkyl is alkyl with 1-4 carbon atoms. The alkoxy is any one of methoxy and ethoxy. The substituted alkoxy group is a haloalkoxy group, more preferably, the substituted alkoxy group is a chloroalkoxy group or a fluoroalkoxy group, still more preferably, the substituted alkoxy group is a trifluoroalkoxy group. Further preferred is trifluoroethoxy. The ester group is methyl formate group. Aryl is any one of phenyl and substituted phenyl. The substituted phenyl group is preferably a halogenated phenyl group.
For R3, preferably, the aryl is any one of phenyl, substituted phenyl and naphthyl; the aryl-heteroaryl group is thienyl. The substituted phenyl is any one of tolyl, xylyl, ethylphenyl, diethylphenyl, tolyl, methoxyphenyl and halogenated phenyl. The halogenated phenyl is any one of a chlorophenyl, a fluorophenyl and a difluorophenyl. Further preferably, the halogenated phenyl group is any one of a 2-chlorophenyl group, a 2, 4-difluorophenyl group, a 4-fluorophenyl group, a 4-chlorophenyl group and a 4-bromophenyl group. Alternatively, the substituted phenyl group may be any one of 4-methylphenyl group, 4-trifluoromethylphenyl group, 4-methoxyphenyl group and 3, 4-dimethoxyphenyl group. The aryl heteroaryl is any one of thienyl, 2-thienyl and 3-pyridyl.
The preparation method of the benzoyl pyridazine derivative comprises the following steps:
1) Uniformly mixing a compound shown in a formula 3, a compound shown in a formula 4, a catalyst, an oxidant and an additive in a solvent, and reacting for 5-8h at 55-65 ℃;
r1 is any one of halogen, alkyl and alkoxy;
r2 is any one of halogen, alkyl and alkoxy;
r3 is any one of phenyl and substituted phenyl;
the additive is any one of trifluoroacetic acid and sulfuric acid;
2) Neutralizing the system after the reaction in the step 1), and then extracting and separating to obtain the catalyst.
The preparation method of the benzoyl pyridazine derivative has the advantages of low reaction temperature, wide substrate application range and short route by utilizing Minisci free radical reaction in a synthetic route, is an ideal aroylation reaction of the pyridazine compound, and is suitable for large-scale production. The preparation method of the invention has the advantages of stable raw materials, low cost, high reaction yield and obvious economic effect.
Further, the molar ratio of the compound shown in the formula 3 to the compound shown in the formula 4 in the step 1) is 1:1.2-1.8.
Further, the molar ratio of the compound shown in the formula 3 in the step 1) to the catalyst is 1:0.2-0.5.
Further, the molar ratio of the compound shown in the formula 3 in the step 1) to the oxidant is 1:1.4-2.0.
Further, the ratio of the compound represented by formula 3 to the solvent in step 1) is 10mL of the solvent per 1g of the compound represented by formula 3.
Further, the molar ratio of the compound shown in the formula 3 to the additive in the step 1) is 1:1-1.5.
Further, the catalyst is any one of silver nitrate, silver sulfate and silver trifluoroacetate.
Further, the oxidant is at least one of sodium persulfate, potassium persulfate and ammonium persulfate.
Further, the extractant used in the extraction in the step 2) is ethyl acetate.
Further, the separation in step 2) employs column chromatography.
Further, in step 1), the solvent is water. The neutralization in step 2) employs a saturated sodium carbonate solution.
The invention has the beneficial effects that:
the preparation method of the benzoyl pyridazine derivative has the advantages of mild reaction conditions, wide substrate application range, short route, simple operation, stable raw materials, lower cost and high yield, and is suitable for large-scale production.
Drawings
FIG. 1 is a nuclear magnetic resonance spectrum of a benzoylpyridazine derivative of example 1;
FIG. 2 is a nuclear magnetic resonance spectrum of a benzoylpyridazine derivative of example 8;
FIG. 3 is a nuclear magnetic resonance spectrum of a benzoylpyridazine derivative of example 9;
FIG. 4 is a nuclear magnetic resonance spectrum of the benzoylpyridazine derivative of example 10;
FIG. 5 is a nuclear magnetic resonance spectrum of a benzoylpyridazine derivative of example 11;
FIG. 6 is a nuclear magnetic resonance spectrum of a benzoylpyridazine derivative of example 12;
FIG. 7 is a nuclear magnetic resonance spectrum of a benzoylpyridazine derivative of example 13;
FIG. 8 is a nuclear magnetic resonance spectrum of a benzoylpyridazine derivative of example 14;
FIG. 9 is a nuclear magnetic resonance spectrum of a benzoylpyridazine derivative of example 15;
FIG. 10 is a nuclear magnetic resonance spectrum of a benzoylpyridazine derivative of example 16;
FIG. 11 is a nuclear magnetic resonance spectrum of a benzoylpyridazine derivative of example 17;
FIG. 12 is a nuclear magnetic resonance spectrum of a benzoylpyridazine derivative of example 18;
FIG. 13 is a nuclear magnetic resonance spectrum of a benzoylpyridazine derivative of example 19;
FIG. 14 is a nuclear magnetic resonance spectrum of a benzoylpyridazine derivative of example 20;
FIG. 15 is a nuclear magnetic resonance spectrum of a benzoylpyridazine derivative of example 22;
FIG. 16 is a nuclear magnetic resonance spectrum of a benzoylpyridazine derivative of example 23;
FIG. 17 is a nuclear magnetic resonance spectrum of a benzoylpyridazine derivative of example 24;
FIG. 18 is a nuclear magnetic resonance spectrum of a benzoylpyridazine derivative of example 25;
FIG. 19 is a nuclear magnetic resonance spectrum of a benzoylpyridazine derivative of example 26;
FIG. 20 is a nuclear magnetic resonance spectrum of a benzoylpyridazine derivative of example 27;
FIG. 21 is a nuclear magnetic resonance spectrum of a benzoylpyridazine derivative of example 29;
FIG. 22 is a nuclear magnetic resonance spectrum of a benzoylpyridazine derivative of example 30;
FIG. 23 is a nuclear magnetic resonance spectrum of a benzoylpyridazine derivative of example 31;
FIG. 24 is a nuclear magnetic resonance spectrum of a benzoylpyridazine derivative of example 32;
FIG. 25 is a nuclear magnetic resonance spectrum of a benzoylpyridazine derivative of example 33;
FIG. 26 is a nuclear magnetic resonance spectrum of a benzoylpyridazine derivative of example 34;
FIG. 27 is a nuclear magnetic resonance spectrum of a benzoylpyridazine derivative of example 35;
FIG. 28 is a nuclear magnetic resonance spectrum of a benzoylpyridazine derivative of example 36.
Detailed Description
In order to make the technical problems, technical schemes and beneficial effects solved by the invention easier to understand, the invention is described in detail below with reference to specific embodiments.
Example 1
The benzoyl pyridazine derivative of the embodiment is 3-chloro-4-benzoyl-6-methoxypyridazine, and the specific structure is shown in the following formula:
the preparation method of the benzoylpyridazine derivative of this example includes the following steps:
1) A clean three-port bottle with the volume of 500mL is taken, 150mL of deionized water, 14.4g (0.1 mol) of 3-chloro-6-methoxypyridazine, 22.5g (0.15 mol) of benzoyl formic acid, 35.7g (0.15 mol) of sodium persulfate, 7.5mL (0.1 mol) of trifluoroacetic acid and 3.4g (0.02 mol) of silver nitrate are added into the three-port bottle, and after the three-port bottle is uniformly mixed, the liquid temperature in the three-port bottle is heated to 60 ℃, and then the three-port bottle is stirred for reaction for 6 hours;
2) Adding saturated sodium carbonate solution into the three-mouth bottle after the reaction in the step 1), stirring and mixing uniformly to neutralize, and extracting with ethyl acetate three times, wherein 100mL of ethyl acetate is used each time; the organic phase was then concentrated by drying and then separated by column chromatography to give 15.2g of the product 3-chloro-4-benzoyl-6-methoxypyridazine (yield 62%).
The melting point of the 3-chloro-4-benzoyl-6-methoxypyridazine obtained was measured to be 96-97 ℃.
The nuclear magnetism detection result of the product is as follows: 1 H NMR(400MHz,CDCl 3 ):δ7.76(d,J＝7.7Hz,2H),7.68-7.65(m,1H),7.52-7.49(m,2H),7.39(s,1H),4.08(s,3H)。 13 C NMR(100MHz,CDCl 3 ):δ164.0,159.2,157.6,136.6,131.2,129.2,127.3,117.2；LC-MS(m/z):157.1[M+H] + 。
example 2
The benzoyl pyridazine derivative of the embodiment is 3-chloro-4-benzoyl-6-methoxypyridazine, and the specific structure is shown in the following formula:
the preparation method of the benzoylpyridazine derivative of this example includes the following steps:
1) A clean three-port bottle with the volume of 500mL is taken, 150mL of deionized water, 14.4g (0.1 mol) of 3-chloro-6-methoxypyridazine, 18g (0.12 mol) of benzoic acid, 38g (0.16 mol) of sodium persulfate, 11.1mL (0.15 mol) of trifluoroacetic acid and 3.4g (0.02 mol) of silver nitrate are added into the three-port bottle, and after the three-port bottle is uniformly mixed, the temperature of liquid in the three-port bottle is 60 ℃, and then the three-port bottle is heated to be stirred for reaction for 6 hours;
2) Adding saturated sodium carbonate solution into the three-mouth bottle after the reaction in the step 1), stirring and mixing uniformly to neutralize, and extracting with ethyl acetate three times, wherein 100mL of ethyl acetate is used each time; the organic phase was then concentrated by drying and then separated by column chromatography to give 15.8g of the product 3-chloro-4-benzoyl-6-methoxypyridazine (yield 63.5%).
The melting point of the 3-chloro-4-benzoyl-6-methoxypyridazine obtained was measured to be 96-97 ℃.
The nuclear magnetism detection result of the product is as follows: 1 H NMR(400MHz,CDCl 3 ):δ7.76(d,J＝7.7Hz,2H),7.68-7.65(m,1H),7.52-7.49(m,2H),7.39(s,1H),4.08(s,3H)。 13 C NMR(100MHz,CDCl 3 ):δ164.0,159.2,157.6,136.6,131.2,129.2,127.3,117.2；LC-MS(m/z):157.1[M+H] + 。
example 3
The benzoyl pyridazine derivative of the embodiment is 3-chloro-4-benzoyl-6-methoxypyridazine, and the specific structure is shown in the following formula:
the preparation method of the benzoylpyridazine derivative of this example includes the following steps:
1) A clean three-port bottle with the volume of 500mL is taken, 150mL of deionized water, 14.4g (0.1 mol) of 3-chloro-6-methoxypyridazine, 24g (0.16 mol) of benzoyl formic acid, 42.8g (0.18 mol) of sodium persulfate, 8.9mL (0.12 mol) of trifluoroacetic acid and 5g (0.03 mol) of silver nitrate are added into the three-port bottle, and after the three-port bottle is uniformly mixed, the temperature of liquid in the three-port bottle is heated to 55 ℃, and then the three-port bottle is stirred for reaction for 8 hours;
2) Adding saturated sodium carbonate solution into the three-mouth bottle after the reaction in the step 1), stirring and mixing uniformly to neutralize, and extracting with ethyl acetate three times, wherein 100mL of ethyl acetate is used each time; the organic phase was then concentrated by drying and then separated by column chromatography to give 14.9g of the product 3-chloro-4-benzoyl-6-methoxypyridazine (yield 59.8%).
The melting point of the 3-chloro-4-benzoyl-6-methoxypyridazine obtained was measured to be 96-97 ℃.
The nuclear magnetism detection result of the product is as follows: 1 H NMR(400MHz,CDCl 3 ):δ7.76(d,J＝7.7Hz,2H),7.68-7.65(m,1H),7.52-7.49(m,2H),7.39(s,1H),4.08(s,3H)。 13 C NMR(100MHz,CDCl 3 ):δ164.0,159.2,157.6,136.6,131.2,129.2,127.3,117.2；LC-MS(m/z):157.1[M+H] + 。
example 4
The benzoyl pyridazine derivative of the embodiment is 3-chloro-4-benzoyl-6-methoxypyridazine, and the specific structure is shown in the following formula:
the preparation method of the benzoylpyridazine derivative of this example includes the following steps:
1) A clean three-port bottle with the volume of 500mL is taken, 150mL of deionized water, 14.4g (0.1 mol) of 3-chloro-6-methoxypyridazine, 22.5g (0.15 mol) of benzoyl formic acid, 35.7g (0.15 mol) of sodium persulfate, 7.5mL (0.1 mol) of trifluoroacetic acid and 3.4g (0.02 mol) of silver nitrate are added into the three-port bottle, and after the three-port bottle is uniformly mixed, the liquid temperature in the three-port bottle is heated to 65 ℃, and then the three-port bottle is stirred for reaction for 5 hours;
2) Adding saturated sodium carbonate solution into the three-mouth bottle after the reaction in the step 1), stirring and mixing uniformly to neutralize, and extracting with ethyl acetate three times, wherein 100mL of ethyl acetate is used each time; the organic phase was then concentrated by drying and then separated by column chromatography to give 14.5g of the product 3-chloro-4-benzoyl-6-methoxypyridazine (yield 58.2%).
The melting point of the 3-chloro-4-benzoyl-6-methoxypyridazine obtained was measured to be 96-97 ℃.
The nuclear magnetism detection result of the product is as follows: 1 H NMR(400MHz,CDCl 3 ):δ7.76(d,J＝7.7Hz,2H),7.68-7.65(m,1H),7.52-7.49(m,2H),7.39(s,1H),4.08(s,3H)。 13 C NMR(100MHz,CDCl 3 ):δ164.0,159.2,157.6,136.6,131.2,129.2,127.3,117.2；LC-MS(m/z):157.1[M+H] + 。
example 5
The benzoyl pyridazine derivative of the embodiment is 3-chloro-4, 5-dibenzoyl-6-chloropyridazine, and the specific structure is shown as the following formula:
the preparation method of the benzoylpyridazine derivative of this example includes the following steps:
1) A clean three-port bottle with the volume of 500mL is taken, 150mL of deionized water, 14.9g (0.1 mol) of 3-chloro-6-chloropyridazine, 30g (0.2 mol) of benzoyl formic acid, 54g (0.2 mol) of potassium persulfate, 8.9mL (0.12 mol) of trifluoroacetic acid and 8.5g (0.05 mol) of silver nitrate are added into the three-port bottle, and after the three-port bottle is uniformly mixed, the temperature of liquid in the three-port bottle is heated to 60 ℃, and then the three-port bottle is stirred for reaction for 6 hours;
2) Adding saturated sodium carbonate solution into the three-mouth bottle after the reaction in the step 1), stirring and mixing uniformly to neutralize, and extracting with ethyl acetate three times, wherein 100mL of ethyl acetate is used each time; the organic phase was then concentrated by drying and then separated by column chromatography to give 18.3g of the product 3-chloro-4, 5-dibenzoyl-6-chloropyridazine (yield 52%).
Example 6
The benzoyl pyridazine derivative of the embodiment is 3-chloro-4-benzoyl-6-iodopyridazine, and the specific structure is shown in the following formula:
the preparation method of the benzoylpyridazine derivative of this example includes the following steps:
1) A clean three-port bottle with the volume of 500mL is taken, 150mL of deionized water and 36.7g (0.1 mol) of 3-chloro-6-iodopyridazine, 22.5g (0.15 mol) of benzoyl formic acid, 35.7g (0.15 mol) of sodium persulfate, 7.5mL (0.1 mol) of trifluoroacetic acid and 4.4g (0.02 mol) of silver trifluoroacetate are added into the three-port bottle, and after the three-port bottle is uniformly mixed, the three-port bottle is heated to the liquid temperature of 60 ℃ and then stirred for reaction for 6h;
2) Adding saturated sodium carbonate solution into the three-mouth bottle after the reaction in the step 1), stirring and mixing uniformly to neutralize, and extracting with ethyl acetate three times, wherein 100mL of ethyl acetate is used each time; the organic phase was then concentrated by drying and then separated by column chromatography to give 213g of the product 3-chloro-4-benzoyl-6-iodopyridazine (yield 45%).
Example 7
The benzoyl pyridazine derivative of the embodiment is 3-chloro-4-benzoyl-6-methyl pyridazine, and the specific structure is shown in the following formula:
the preparation method of the benzoylpyridazine derivative of this example includes the following steps:
1) A clean three-port bottle with the volume of 500mL is taken, 150mL of deionized water and 12.85g (0.1 mol) of 3-chloro-6-methylpyridazine, 22.5g (0.15 mol) of benzoyl formic acid, 35.7g (0.15 mol) of sodium persulfate, 7.5mL (0.1 mol) of trifluoroacetic acid and 4.4g (0.02 mol) of silver trifluoroacetate are added into the three-port bottle, and after the mixture is uniformly mixed, the three-port bottle is heated to the liquid temperature of 60 ℃ in the three-port bottle, and then stirred for reaction for 6 hours;
2) Adding saturated sodium carbonate solution into the three-mouth bottle after the reaction in the step 1), stirring and mixing uniformly to neutralize, and extracting with ethyl acetate three times, wherein 100mL of ethyl acetate is used each time; the organic phase was then concentrated by drying and then separated by column chromatography to give 13.8g of the product 3-chloro-4-benzoyl-6-methylpyridazine (yield 59%).
The structures of the benzoylpyridazine derivatives in examples 8 to 38 and the related test data are shown in the following table, and the preparation method thereof can be referred to the preparation method in example 1.
TABLE 1 Structure and Properties of benzoylpyridazine derivatives in examples 8-38
/>
/>
/>
The benzoyl pyridazine derivative can be used as an energy material and an organic luminescent material. When being used as an organic luminescent material, the organic luminescent material has better thermal stability and higher quantum efficiency, and the external quantum efficiency of the green phosphorescence organic luminescent device prepared by the organic luminescent material can exceed 22 percent. Can also be used as medicine, such as TYK2 inhibitor, and has good pharmacokinetic properties.

Claims (1)

1. A method for producing a benzoylpyridazine derivative, characterized in that the benzoylpyridazine derivative has a structure represented by formula 1:
；
the preparation method comprises the following steps:
1) Uniformly mixing a compound shown in a formula 3, a compound shown in a formula 4, a catalyst, an oxidant and an additive in a solvent, and reacting for 5-8h at 55-65 ℃;
；
r1 is hydrogen; r2 is hydrogen;
r3 is phenyl;
2) Neutralizing the system after the reaction in the step 1), and then extracting and separating to obtain the catalyst;
the molar ratio of the compound shown in the formula 3 to the compound shown in the formula 4 in the step 1) is 1:1.2-2;
the molar ratio of the compound shown in the formula 3 in the step 1) to the catalyst is 1:0.2-0.5;
the molar ratio of the compound shown in the formula 3 in the step 1) to the oxidant is 1:1.4-2.0;
the catalyst is any one of silver nitrate, silver sulfate and silver trifluoroacetate;
the oxidant is at least one of sodium persulfate, potassium persulfate and ammonium persulfate;
the additive is any one of trifluoroacetic acid and sulfuric acid;
the molar ratio of the compound shown in the formula 3 in the step 1) to the additive is 1:1-1.5;
the neutralization in step 2) adopts saturated sodium carbonate solution;
the ratio of the compound shown in the formula 3 to the solvent in the step 1) is that 10mL of solvent is correspondingly adopted for each 1g of the compound shown in the formula 3;
the extractant adopted in the extraction in the step 2) is ethyl acetate;
the separation in step 2) is carried out by column chromatography.
CN202010578951.2A 2020-06-23 2020-06-23 Benzoyl pyridazine derivative and preparation method thereof Active CN111662235B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010578951.2A CN111662235B (en) 2020-06-23 2020-06-23 Benzoyl pyridazine derivative and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010578951.2A CN111662235B (en) 2020-06-23 2020-06-23 Benzoyl pyridazine derivative and preparation method thereof

Publications (2)

Publication Number Publication Date
CN111662235A CN111662235A (en) 2020-09-15
CN111662235B true CN111662235B (en) 2023-12-22

Family

ID=72389339

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010578951.2A Active CN111662235B (en) 2020-06-23 2020-06-23 Benzoyl pyridazine derivative and preparation method thereof

Country Status (1)

Country Link
CN (1) CN111662235B (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003091226A1 (en) * 2002-04-26 2003-11-06 Eli Lilly And Company Triazole derivatives as tachykinin receptor antagonists
WO2008085008A1 (en) * 2007-01-11 2008-07-17 Mogam Biotechnology Research Institute T-cell inhibiting compounds and their use for the treatment of t-cell-mediated diseases
CN110240568A (en) * 2019-04-01 2019-09-17 兰州大学 Three replace pyridazine analog derivative and preparation method thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003091226A1 (en) * 2002-04-26 2003-11-06 Eli Lilly And Company Triazole derivatives as tachykinin receptor antagonists
WO2008085008A1 (en) * 2007-01-11 2008-07-17 Mogam Biotechnology Research Institute T-cell inhibiting compounds and their use for the treatment of t-cell-mediated diseases
CN110240568A (en) * 2019-04-01 2019-09-17 兰州大学 Three replace pyridazine analog derivative and preparation method thereof

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
2302448-22-0/RN;ACS;《STN REGISTRY》;20190407;第1-19页 *
Boamah, Philip Yaw 等.Pyridazines. XLI. Synthesis of novel pyrido[3,4-d]pyridazine derivatives from 4,5-disubstituted pyridazines.《Journal of Heterocyclic Chemistry》.1989,第26卷第933-939页. *
Eichhorn, Thomas A. 等.Synthesis of new aryl (3,6-dichloro-4-pyridazinyl) ketones and their reaction with N,N-dinucleophiles.《Helvetica Chimica Acta》.1988,第71卷第988-991页. *
Kevin D. Hesp 等.Late-stage synthesis and application of photoreactive probes derived from direct benzoylation of heteroaromatic C-H bonds.《Org. Biomol. Chem.》.2020,第18卷第3669-3673页. *
Late-stage synthesis and application of photoreactive probes derived from direct benzoylation of heteroaromatic C-H bonds;Kevin D. Hesp 等;《Org. Biomol. Chem.》;20200506;第18卷;Supporting Information 第S2页和第S4页 *
Pyridazines. XLI. Synthesis of novel pyrido[3,4-d]pyridazine derivatives from 4,5-disubstituted pyridazines;Boamah, Philip Yaw 等;《Journal of Heterocyclic Chemistry》;19890831;第26卷;第933页路线1 *
Regio- and Chemoselective Zincation of Sensitive and Moderately Activated Aromatics and Heteroaromatics Using TMPZnCl 3 LiCl;Tomke Bresser 等;《J. Org. Chem.》;20100617;第75卷;第4689页表3 *
Synthesis of new aryl (3,6-dichloro-4-pyridazinyl) ketones and their reaction with N,N-dinucleophiles;Eichhorn, Thomas A. 等;《Helvetica Chimica Acta》;19881231;第71卷;第989页路线1 *
袁开基 等.二嗪类-总论，又哒嗪.《有机杂环化学》.人民卫生出版社出版,1984,第227-228页. *

Also Published As

Publication number Publication date
CN111662235A (en) 2020-09-15

Similar Documents

Publication Publication Date Title
CN111499586B (en) Synthesis method of 5,5' -triazene bridged bis (2-methyl-4-nitro-1, 2, 3-triazole) compound
CN112939986B (en) Synthesis method of pyrazolopyrimidine compound
CN104177388A (en) Bridged bisamido rare-earth amide compounds, and preparation method and application thereof
CN103172480B (en) Method for preparing iodo aromatic hydrocarbon
CN111662235B (en) Benzoyl pyridazine derivative and preparation method thereof
CN113416150A (en) Novel synthesis method of lobaplatin intermediate
CN113105357A (en) Synthesis method and application of novel p-aryl azophenol derivative
CN115197153B (en) Preparation method of 1, 4-diazacycloalkane compound
CN114853658B (en) Synthesis method of 9- (4-bromophenyl) carbazole
CN112778317B (en) Synthetic method of [1,2,4] triazolo [1,5-a ] pyrimidine compound
CN110294781B (en) Schiff base containing ferrocenyl thiadiazole base and preparation method thereof
CN114478245A (en) Asymmetric synthesis method of chiral gamma-alkynyl-alpha-keto acid ester compound
CN108409672B (en) Method for synthesizing polysubstituted pyrimidine under catalysis of copper salt
CN108727323B (en) Method for catalytically synthesizing trifluoromethyl substituted homoisoflavone compound by using N-heterocyclic carbene
CN113121354A (en) Synthesis method of substituted biphenyl compound
CN113856764B (en) Transition metal catalyst and preparation method and application thereof
CN115010574B (en) Synthesis method of 1-bromo-2-chloro-4-fluoro-2-iodobenzene
CN111909057B (en) Preparation method of cyclopentenyl aryl ketoxime compound
CN108203440B (en) Solvent-free double-screw extrusion continuous synthesis process of potassium aryl trifluoroborate
CN103073498A (en) Novel preparation method for (R)-Alpha-amino-e-caprolactam
CN114805289B (en) Preparation method of 1, 4-oxathia-3, 5-dialdehyde cyclohexadiene compound
CN110746337B (en) Synthesis method of 1-methyl-2-cyano-3-aliphatic substituted azole compound
CN109232579B (en) Method for synthesizing pemetrexed intermediate pemetrexed benzoic acid
CN110483430B (en) Preparation method of isoxazole derivative
CN108822060B (en) 3-aryl substituted oxetane and preparation method thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant